Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study

Wierda, W. G., Shah, N. N., Cheah, C. Y., Lewis, D., Hoffmann, M. S., Coombs, C. C., Lamanna, N., Ma, S., Jagadeesh, D., Munir, T., Wang, Y., Eyre, T. A., Rhodes, J. M., McKinney, M., Lech-Maranda, E., Tam, C. S., Jurczak, W., Izutsu, K., Alencar, A. J., … Ghia, P. (2024). Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study. The Lancet Haematology, 11(9), e682–e692. https://doi.org/10.1016/s2352-3026(24)00172-8
Authors:
William G Wierda
Nirav N Shah
Chan Y Cheah
David Lewis
Marc S Hoffmann
Catherine C Coombs
Nicole Lamanna
Shuo Ma
Deepa Jagadeesh
Talha Munir
Yucai Wang
Toby A Eyre
Joanna M Rhodes
Matthew McKinney
Ewa Lech-Maranda
Constantine S Tam
Wojciech Jurczak
Koji Izutsu
Alvaro J Alencar
Manish R Patel
John F Seymour
Jennifer A Woyach
Philip A Thompson
Paolo B Abada
Caleb Ho
Samuel C McNeely
Narasimha Marella
Bastien Nguyen
Chunxiao Wang
Amy S Ruppert
Binoj Nair
Hui Liu
Donald E Tsai
Lindsey E Roeker
Paolo Ghia
Affiliated Authors:
Nicole Lamanna
Columbia Affiliation:
Subjects:
Agammaglobulinaemia Tyrosine Kinase (MeSH)
Protein Kinase Inhibitors (MeSH)
elink
Publication Type:
Article
Unique ID:
10.1016/s2352-3026(24)00172-8
PMID:
39033770
DOI:
10.1016/s2352-3026(24)00172-8
Journal:
Lancet Haematology
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Web of Science Record
View Scopus Record

Record Created: